Neuroendocrine Tumor Research Foundation

10/23/2026

NET, NEN, NEC, high grade, well differentiated. Patients with neuroendocrine cancer face a confusing set of terms, and the field doesn’t always use them consistently.

That inconsistency starts in research and pathology, then carries into the information patients rely on to understand their diagnosis. This is meaningful because neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) can have very different biology, treatments, and clinical trials.

Learn more about neuroendocrine cancer terminology and how NETRF aims for clearer language across research and patient education.

Read the blog ➡️ https://ow.ly/jMCP5100HCe

10/15/2026

Two people with neuroendocrine tumors (NETs) can receive the same treatment and have very different results. Why?

And, if there's a promising therapy for another type of cancer, could it also work for NETs?

In the latest installment of You Ask, NETRF Answers, we take on some of the questions we often hear from our community and explain what researchers are learning about why treatments work differently from person to person.

Learn more ➡️ https://ow.ly/bksT50ZYcoR

10/05/2026

In recognition of World Neuroendocrine Cancer Day on November 10, join NETRF for Thrivership Connect, a free virtual program focused on cultivating emotional well-being and resilience while living with neuroendocrine cancer.

Living with neuroendocrine cancer is about more than managing a diagnosis. It is also about caring for your emotional well-being, adapting to change, finding strength, and staying connected to what matters most.

Together, we will explore practical strategies for navigating the emotional challenges of cancer, strengthening resilience, supporting mental health, and finding ways to live well through uncertainty and change.

Tuesday, November 10, 2026
7:00 p.m. ET
Interactive Virtual Program

Come to learn, connect, share, and leave with practical tools to support your well-being throughout your neuroendocrine cancer journey.

Register now ➡️ https://ow.ly/97bw50ZUI4c

#

10/01/2026

🚨The 2026 edition of Neuroendocrine Cancer: A Guide for Patients and Families is here. 🎉

NETRF's guide for patients and families has been a trusted resource for thousands of patients and caregivers navigating a neuroendocrine cancer diagnosis. The updated 2026 edition offers the reliable information patients and families have come to depend on, while expanding the guide to reflect advances in care and the evolving needs of the neuroendocrine cancer community.

What else is new?
The new edition adds comprehensive information on neuroendocrine carcinoma (NEC), a new chapter on thrivership, and updated statistics.

Order now ➡️ https://ow.ly/8rOQ50ZTAjt

Already ordered a printed guide this year? Your new printed copy is shipping soon.

Carcinoma

Neuroendocrine Cancer: A Guide for Patients and Families Neuroendocrine Cancer: A Guide for Patients and Families The Neuroendocrine Cancer: A Guide for Patients and Families guide has long been a practical, hands-on resource for understanding the tests, treatments, and day-to-day management of neur...

09/25/2026

The North American Neuroendocrine Tumor Society (NANETS) and the Neuroendocrine Tumor Research Foundation (NETRF) are proud to announce that Majid Momeny, PhD, of the McGovern Medical School at UTHealth Houston is the recipient of the 2026 NANETS Basic/Translational Science Investigator Award, a two year, $100,000 grant funded by NETRF.

Poorly differentiated neuroendocrine carcinoma often returns after chemotherapy. Dr. Momeny is studying a protein that helps these tumor cells survive treatment, and testing whether blocking that protein can make chemotherapy more effective. This project has the potential to transform the treatment of neuroendocrine carcinoma.

Learn more ➡️https://ow.ly/j3La50ZRvMj

09/14/2026

GLP-1s have become a widespread and effective tool for treating diabetes and obesity, and their use is expanding to other conditions. For people with neuroendocrine cancer and their clinicians, there's a growing need to know more about how GLP-1s may interact with their disease or treatment plan.

In this episode of NETWise, we look at what researchers and clinicians know so far about GLP-1 medications and neuroendocrine tumors—and what we still don’t know. Some neuroendocrine tumors express the GLP-1 receptor targeted by these medications, but new research suggests that receptor expression varies considerably by tumor type.

We also explore another important consideration for people with cancer: how the appetite suppression and weight loss associated with GLP-1s can affect nutrition, muscle mass, strength, and treatment.

Listen as experts in the field break down the evolving science to help you make the most informed decisions.

Tune in here or wherever you listen to podcasts🎧➡️https://ow.ly/w2iJ50ZNy08

09/09/2026

This week, NETRF CEO Elyse Gellerman joined patient advocates from around the world at the annual INCA (International Neuroendocrine Cancer Alliance) Summit.

Together, they shared successes and challenges in raising awareness, strengthening patient advocacy, and expanding access to treatment for people facing neuroendocrine cancer.

Elyse also presented NETRF's recent work to bring the patient voice directly into research, a step toward ensuring those most affected help shape what comes next.

First photo left to right: Elyse Gellerman, NETRF CEO; Dr. Jaydira del Rivero of the NIH; Teodora Kolarova, INCA Executive Director; and Isabella Oronova, INCA Project Officer

09/03/2026

Style Meets Impact 💜

Citizens of Humanity donated $28,000 to NETRF through sales of The Lindz, a jean created in honor of Lindsay May Palevsky.

Lindsay was a devoted daughter, wife, mother and cherished friend who was known for her grace, resilience, and love of butterflies. Throughout 2025, $50 from every pair of The Lindz sold went directly to funding neuroendocrine cancer research.

Thank you to Jared Freedman and the Citizens of Humanity team, to Lindsay's husband Jon Palevsky and her friend Simone Harouche, and to everyone who purchased a pair. Each one honors Lindsay's life and helps advance research that offers hope to people affected by neuroendocrine cancer.

Lindsay's legacy lives on through the people who loved her, and through the research this gift will help fund.

Pictured: NETRF Board members Elaine Nord (left) and Carrie Camino (right) sporting their Lindz jeans at a recent board meeting.

🦋 Read more ➡️ https://ow.ly/BOEg50ZJ01c

The Neuroendocrine Tumor Research Foundation (NETRF) is deeply grateful to Citizens of Humanity for donating $28,000 through the sale of The Lindz, a jean created in honor of Lindsay May Palevsky. Citizens of Humanity has a longstanding tradition of naming its styles after women who inspire the comp...

08/31/2026

When it comes to a cancer diagnosis, using precise language is critical.

Referring to a pancreatic neuroendocrine tumor (PanNET) as “pancreatic cancer” can direct patients toward information about a disease they do not have, including different survival statistics, treatment approaches, expectations, specialists, and research.

Pancreatic Cancer and PanNETs are two separate diseases, and the differentiation shapes what patients and caretakers understand and what happens after diagnosis.

Learn more about how these two diseases differ and why that difference is so important.

➡️https://ow.ly/Oph950ZHp4s

08/28/2026

Why do some neuroendocrine tumors (NETs) grow slowly for years, while others progress more quickly?

Researchers have often looked to DNA for answers, but more recently they are investigating epigenetics. Epigenetics controls which genes are turned on or off, and how strongly they're expressed.

A new study summarizes what researchers currently know about epigenetic changes in NETs and how these discoveries could eventually improve diagnosis, prognosis, and treatment.

Learn more 🔗 https://ow.ly/tGhV50ZGEWU